You can argue that the other 'James' CEO, James Graham at Recce is not great, but he has raised money into an anti infective asset that is virtually impossible to fund cf oncology drugs and he DID NOT scrape the dregs with an ATM. He also informs share holders as key cohort milestones are met AND what is happening in patients on compassionate use programs. We need to take a leaf out of that book, not all of them. The next pandemic of AMR is already here, in 10 years it will kill more people annually than cancer, unless Recce and others get some totally new anti infectives on the market. I'll be loading some more Recce once Kazia data drops!
KZA Price at posting:
16.5¢ Sentiment: None Disclosure: Held
